rosiglitazone has been researched along with angiotensinogen in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ailhaud, G; Aubert, J; Negrel, R; Safonova, I | 1 |
| Didion, SP; Faraci, FM; Mathur, S; Ryan, MJ; Sigmund, CD | 1 |
2 other study(ies) available for rosiglitazone and angiotensinogen
| Article | Year |
|---|---|
Insulin down-regulates angiotensinogen gene expression and angiotensinogen secretion in cultured adipose cells.
Topics: 3T3 Cells; Adipose Tissue; Angiotensinogen; Animals; Cells, Cultured; Down-Regulation; Gene Expression Regulation; Hypoglycemic Agents; Insulin; Mice; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Tumor Necrosis Factor-alpha | 1998 |
PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice.
Topics: Angiotensinogen; Animals; Antihypertensive Agents; Aorta; Blood Pressure; Endothelium, Vascular; Humans; Hypertension; Mice; Mice, Transgenic; Receptors, Cytoplasmic and Nuclear; Renin; Rosiglitazone; Thiazolidinediones; Transcription Factors; Vasodilation | 2004 |